AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$LQDA

Adair Jason sold $5.1M of LQDA

Adair Jason (Chief Business Officer) sold 73,631 shares of Liquidia Corp (LQDA) at $69.09 ($5.09M total) across 2 trades on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Adair Jason
Published Aug 25, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as reduced confidence.

02

Market read

Insider sales of this size from a C‑suite officer are noteworthy for traders monitoring biotech stocks.

03

What to watch

Upcoming clinical trial data could offset selling pressure if results are positive.

Relevance 5/10Novelty 7/10Timing: today

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Chief Business Officer sold 73,631 shares for $5.1M via a 10b5‑1 plan, reducing his stake to 174,606 shares.

Expected impact

Modest downward pressure over the next few days.

Evidence & confidence

C‑suite insider selling $5M is material for a mid‑cap biotech; market often reacts negatively to such sales.

Market effects

Sector

May raise questions about insider confidence in the biotech sector.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Liquidia Corp

    Biotech firm developing drug delivery platforms.

  • Person
    Adair Jason

    Chief Business Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com